Cancer Care Ontario | Cancer Care Ontario

olaparib - In combination with abiraterone, and prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC), based on criteria

ODB - General Benefit

prednisone

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Dec 2024

Guidelines and Advice

An Endorsement of the 2023 European Association of Urology (EAU) -American Society of Clinical Oncology (ASCO) Guidelines on Penile Cancer

Status: Current
ID: Guideline Endorsement C50-CIDAP-2

Nov 2024

Amanda Sheppard

Senior Scientist, Indigenous Cancer Care Unit, Acute and Hospital-Based Care, Ontario Health Lead Scientist amanda.sheppard@ontariohealth.ca

Abridged-FAQs-for-providers-offering-cervical-screening-FR.pdf

MyPractice-Reports-Technical-Appendix.pdf

MyPractice-Reports-Technical-Appendix-French.pdf

MyPractice-Reports-Technical-Appendix-FR

AL-Referral-Information-Package.pdf

AL-Referral-Information-Package-FR.pdf

MFOLFIRINOX

MFOLFOX6+PEMB+TRAS

An Endorsement of the ASTRO/ESTRO 2023 Guideline for the Treatment of Patients with Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer

ABIROLAPPRED

An Endorsement of the 2023 European Association of Urology (EAU) -American Society of Clinical Oncology (ASCO) Guidelines on Penile Cancer

Amanda Sheppard

Pages